IN8Bio Inc. news

• Agreement provides exclusive access to state-of-the-art GMP manufacturing suites to support Phase 2 clinical studies
  
  
• Potential to expand the agreement to support commercial-scale manufacturing

NEW YORK and LOUISVILLE, Ky, Sept. 15, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has

• All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year.
  
  
• Patients remain in morphological complete remission (CR) with two patients over two years and a third over one year post-transplant, respectively.
  
  
• Safety profile continues to be manageable with no dose-limiting toxicities, no treatment-r